News › Clinical Practice, Industry News

Neurotoxin News: The DAXI Differentiator

May 13, 2019

By all accounts, Revance is preparing for the FDA’s approval and market launch of its lead compound daxibotulinumtoxinA for injection (DAXI). DAXI clinical trials looking at glabellar line treatment suggest the neuromodulator with its proprietary peptide technology is at least as good as Botox (onabotulinumtoxinA, Allergan) but lasts substantially longer.
On April 9, Revance announced former Allergan marketing professional Taryn Conway had joined the biotechnology company’s team “… as the company transitions from clinical-stage development to commercialization…,” according to a Revance press release.
Read more at Dermatology Times >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Medical Marketing Whiz Recognized With Healthcare Digital Marketing Excellence Award
    • Allergan Presents Early Data on Skin Quality Treatments for Patients Taking Weight-Loss Medications
    • ValueCap Becomes Silver Vendor Affiliate with the American Med Spa Association
    • FDA Warning Letter Signals Increased Scrutiny of the Medical Necessity Exception for Compounded GLP-1s
    • Allergan Aesthetics Debuts AA Signature in the United States with SKIN360
Advertisement